Biobeat Overview
Biobeat is a med-tech company providing FDA-cleared, cuffless blood pressure monitoring. The small, non-invasive sensor is placed onto the patient’s chest for 24 hours, and the measurements are taken through our proprietary patented PPG sensor. The technology not only allows for blood pressure to be taken, but also extracts heart rate, and cardiac output. The device and automated platform deliver a detailed report to the clinician, immediately after the patient has completed the test. This allows for quick evaluation and treatment plans, and also enables physicians to make proper adjustments on current treatment plans based on the quantitative measures and trends that the blood pressure monitoring solution provides. The Biobeat sensor eliminates white coat and masked hypertension by using a cuffless test. White coat hypertension is a common barrier in ABPM testing, as patients often become stressed when the cuff inflates. However, with Biobeat, patients often forget they are wearing the sensor and do not feel when the readings are being taken. This allows them to go about their daily lives without interruption.
Cumulative Funding Raised Over Time ($)
—Feb 2021
$1.0MJun 2016
$9.0MMar 2020
$11.0MNov 2017
$18.0MSep 2023
Latest News
growth-positive
Toss the cuff: A new blood pressure patch is here
BioBeat has developed a skin patch that uses light to measure blood pressure, heart rate, and blood oxygen levels. The patch is designed to provide a more accurate reading than traditional methods, as it can monitor patients continuously for 24 hours, including while they sleep. This could be particularly useful for detecting undiagnosed high blood pressure that only occurs at night. The patch is already available for patients to use. Researchers at UC San Diego are also developing a smaller wearable ultrasound patch that uses soundwaves to track blood pressure.
Customers
growth-positive
Tampa General launches hospital at-home program
Tampa General Hospital has launched a hospital at home program, using the Biobeat system to monitor patients health metrics in real time from their homes. The program is designed to detect early signs of patient deterioration, allowing for timely interventions and potentially preventing adverse events. The collaboration between Tampa General Hospital and Biobeat is aimed at redefining traditional healthcare models, addressing the evolving needs of patients and aligning with the growing demand for more flexible and personalized healthcare solutions.
CustomersPartners
growth-positive
Biobeat joins Innovators' Network at American Heart Association Center for Health Technology & Innovation
Biobeat has joined the American Heart Association Center for Health Technology & Innovations Innovators Network, a consortium focused on developing innovative and scalable health tech solutions. As a member, Biobeat will have access to the Associations digital guidelines and collaborate with the Center on clinical outcome studies. The companys goal is to improve cardiovascular health and help healthcare providers through their cuffless blood pressure measurement tool and remote patient monitoring platform. Biobeats solution has received FDA clearance and leverages AI and med-tech capabilities to collect and analyze patient data. The company anticipates that its easy-to-wear cuffless health sensor solutions will enable proactive care for hypertension patients.
Partners
growth-positive
FDA clears Biobeat's remote vital sign monitoring system
Biobeat has received FDA 510(k) clearance for its wearable remote patient monitoring device. The clearance allows the device to monitor respiratory rate, body temperature, cuffless blood pressure, blood oxygen saturation, and pulse rate. Biobeats system uses proprietary PPG monitoring technology and connects to a cloud-based patient management system. The system includes an early warning score system and AI-based algorithms for predictive analytics. The CEO of Biobeat sees this milestone as cementing the company as a market leader in remote patient monitoring.
CustomersPartners
growth-positive
Biobeat's AI-Powered Remote Patient Monitoring Platform Receives A Full CE Mark
Biobeat, a global leader in wearable remote patient monitoring solutions, has received a full CE Mark approval for its AI-powered platform. The approval covers Biobeats wrist and chest-patch monitoring devices, which accurately and continuously monitor vital signs. It also includes wireless capabilities and a cloud-based web management platform for healthcare providers. The approval further solidifies Biobeats position as a leading provider of wearable monitoring devices for both hospital and home use. The companys wearable devices utilize non-invasive technology to track 15 cardio-pulmonary vital signs and connect to a cloud-based patient management system. Biobeats solutions are currently used in medical centers worldwide.
CustomersPartners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $18.6M |
| Last funding | $7M |
| Stage | A |
| Rounds | 6 |
| Investors | 5 |
Team Members
6
Employees: 11-50
Web & Social Links
| Website | www.bio-beat.com |
| Careers | Careers page |
Locations
Ef'al St 22, Petah Tikva, Israel
Florida, USA
Photos & Videos
6 item(s)
Biobeat Business
Business models
B2B, B2B2C
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesMedical DevicesMedical MonitorsDigital HealthcarePatient Remote MonitoringTarget Customer
Healthcare & Life SciencesLife SciencesMedical Devices IndustryHealthcareProvidersCore Technology
Semiconductors & ElectronicsWearablesArtificial IntelligenceMachine LearningSensingBiometricsTags (20)
clinical-trialsearly-detectionmonitoringwearablesensorsdecision-supportmedical-technologiesinsurance-companiesmobile-applicationsdiagnosticsreal-timephysiological-parametersmeasurementsseniorstreatmentspharma-companiespersonalizationmachine-learningweb-platformalert-systemGeographic Markets
IsraelEuropeUnited StatesCanadaWestern EuropeGlobalBiobeat Financials
$18.6M
Total funding
Undisclosed
Capital raised
$7M
Last funding
A
Funding stage
6
Total rounds
5
Investors
Cumulative Funding Raised Over Time ($)
—Feb 2021
$1.0MJun 2016
$9.0MMar 2020
$11.0MNov 2017
$18.0MSep 2023
Private Equity Funding
A Round
Sep 2023
$7M
Best Buy Health
Undisclosed Round
Feb 2021
Undisclosed
Infinity Medical
A Round
Mar 2020
$8M
Menomadin Foundation
Seed
Nov 2017
$2M
Undisclosed Investor(s), Co-Share
Seed
Jun 2016
$1M
Undisclosed Investor(s)
Non-Equity Funding
GrantEvent
Dec 2018
$600K
DRIVe
Biobeat Lifecycle
Cumulative Funding Raised Over Time
—Feb 2021
$1.0MJun 2016
$9.0MMar 2020
$11.0MNov 2017
$18.0MSep 2023
All Events
A Round
Sep 2023
$7M
Best Buy Health
Undisclosed Round
Feb 2021
Undisclosed
Infinity Medical
A Round
Mar 2020
$8M
Menomadin Foundation
Seed
Nov 2017
$2M
Undisclosed Investor(s), Co-Share
Seed
Jun 2016
$1M
Undisclosed Investor(s)
GrantEvent
Dec 2018
$600K
DRIVe
Biobeat News
22 articles
growth-positive
Toss the cuff: A new blood pressure patch is here
BioBeat has developed a skin patch that uses light to measure blood pressure, heart rate, and blood oxygen levels. The patch is designed to provide a more accurate reading than traditional methods, as it can monitor patients continuously for 24 hours, including while they sleep. This could be particularly useful for detecting undiagnosed high blood pressure that only occurs at night. The patch is already available for patients to use. Researchers at UC San Diego are also developing a smaller wearable ultrasound patch that uses soundwaves to track blood pressure.
Customers
growth-positive
Tampa General launches hospital at-home program
Tampa General Hospital has launched a hospital at home program, using the Biobeat system to monitor patients health metrics in real time from their homes. The program is designed to detect early signs of patient deterioration, allowing for timely interventions and potentially preventing adverse events. The collaboration between Tampa General Hospital and Biobeat is aimed at redefining traditional healthcare models, addressing the evolving needs of patients and aligning with the growing demand for more flexible and personalized healthcare solutions.
CustomersPartners
growth-positive
Biobeat joins Innovators' Network at American Heart Association Center for Health Technology & Innovation
Biobeat has joined the American Heart Association Center for Health Technology & Innovations Innovators Network, a consortium focused on developing innovative and scalable health tech solutions. As a member, Biobeat will have access to the Associations digital guidelines and collaborate with the Center on clinical outcome studies. The companys goal is to improve cardiovascular health and help healthcare providers through their cuffless blood pressure measurement tool and remote patient monitoring platform. Biobeats solution has received FDA clearance and leverages AI and med-tech capabilities to collect and analyze patient data. The company anticipates that its easy-to-wear cuffless health sensor solutions will enable proactive care for hypertension patients.
Partners
growth-positive
FDA clears Biobeat's remote vital sign monitoring system
Biobeat has received FDA 510(k) clearance for its wearable remote patient monitoring device. The clearance allows the device to monitor respiratory rate, body temperature, cuffless blood pressure, blood oxygen saturation, and pulse rate. Biobeats system uses proprietary PPG monitoring technology and connects to a cloud-based patient management system. The system includes an early warning score system and AI-based algorithms for predictive analytics. The CEO of Biobeat sees this milestone as cementing the company as a market leader in remote patient monitoring.
CustomersPartners
growth-positive
Biobeat's AI-Powered Remote Patient Monitoring Platform Receives A Full CE Mark
Biobeat, a global leader in wearable remote patient monitoring solutions, has received a full CE Mark approval for its AI-powered platform. The approval covers Biobeats wrist and chest-patch monitoring devices, which accurately and continuously monitor vital signs. It also includes wireless capabilities and a cloud-based web management platform for healthcare providers. The approval further solidifies Biobeats position as a leading provider of wearable monitoring devices for both hospital and home use. The companys wearable devices utilize non-invasive technology to track 15 cardio-pulmonary vital signs and connect to a cloud-based patient management system. Biobeats solutions are currently used in medical centers worldwide.
CustomersPartners
growth-positive
Biobeat to Trial Patient Monitoring Devices with Acute Ischemic Stroke Patients -
Biobeat has started a pilot study with Nuvance Healths Vassar Brothers Medical Center to evaluate the use of its continuous monitoring devices with stroke patients. The study aims to measure patient and staff satisfaction and identify any benefits or barriers to implementing the wearable patient monitoring devices. Biobeats wearable devices have the potential to improve patient outcomes by providing real-time health data from a distance. The devices can increase the periodicity of vital signs monitoring, potentially reducing hospital stays and mortality. The pilot study may lead to a change in the standard of care for stroke patients.
CustomersPartners
growth-positive
Biobeat Launches Health AI Hospital At Home Patient Monitoring Kit
Biobeat has launched a new home-based remote patient monitoring kit that allows healthcare providers to remotely monitor patients vital signs and receive updates and deterioration alerts. The solution aims to alleviate hospital overload, reduce costs, and improve patient care. The kit includes chest-monitors, compatible adhesive units, and a user-friendly manual, along with an intuitive mobile app for data sharing. Biobeats AI-powered cloud-based patient management system analyzes the patient data and provides continuous monitoring and predictive patient deterioration alerts. The company expects hospital-level home-based remote patient monitoring solutions to become the standard of patient care in 2021 and beyond. The new system is now available to healthcare providers globally.
CustomersPartners
growth-positive
Arik Ben Ishay, CEO of Biobeat - Interview Series - Unite.AI
Biobeat is an AI-powered remote patient monitoring platform that provides wearable monitors and a cloud-based patient management system. The company was founded by Arik Ben Ishay, Johanan May, and Israel Sarussi. Biobeats monitors track various vital signs and health parameters using proprietary non-invasive reflective photoplethysmography (PPG) technology. The company has recently been recommended by the Israeli Ministry of Health for COVID-19 preparedness. They are implementing their solution in multiple major healthcare provider systems in the US after receiving FDA clearance. Biobeat aims to improve patient outcomes and streamline workflows through their remote monitoring solution.
CustomersPartners
N/A
https://www.fiercebiotech.com/special-report/biobeat-fierce-medtech-s-top-10-m-a-targets-for-2020
The article discusses the terms of use and privacy policy of Questex LLC.
growth-positive
Biobeat Wearable Wrist And Chest Patient Monitoring Solutions Receives Class II Medical Device Approval From Health Canada - Medical Device News Magazine
Biobeat, a provider of wearable remote patient monitoring solutions, has received Class II medical device approval from Health Canada for its wearable wrist and chest patient monitoring solutions. The devices transmit real-time patient data, helping health teams improve patient outcomes and detect patient deterioration. The approval allows Biobeat to offer its technologies to the Canadian healthcare market. Maisha Labs, a Canadian digital health solution provider, assisted Biobeat throughout the licensing process and will continue to play a pivotal role in implementing the company’s solutions in healthcare facilities throughout the country.
CustomersPartners
growth-positive
https://www.jpost.com/health-science/blood-pressure-can-be-meaused-simply-with-biobeats-cuffless-solution-644874
BioBeat, a medical technology innovation firm, has developed a patch-based wireless blood pressure monitoring solution called BioTech. The company combined the patch with a smartwatch to provide users with a more convenient way to monitor their health data. The solution was found to be 96.31% as effective as traditional blood pressure measuring methods in a study. The wearable patch uses light to check blood volume changes and detect heart rate and breathing. It collects data on 16 aspects of the patients health and transmits it to a secure cloud-based server. The patch can be worn for up to 10 days, while the smartwatch needs to be recharged every three days. BioBeat is the first and only company to receive FDA approval for a cuffless solution of this kind. The company aims to revolutionize medical monitoring and prevent deaths from heart attacks and strokes caused by high blood pressure.
Customers
growth-positive
Clinical Study Highlights Accuracy of Biobeat's Wearable Cuffless Blood Pressure Monitoring Device When Compared To Traditional Cuff-Based Devices
Biobeat, a global leader in wearable remote patient monitoring solutions, announced the results of a clinical study comparing blood pressure measurements using its proprietary device and a standard cuff-based device. The study showed that Biobeats device accurately and reliably detects and follows changes in blood pressure over time. The device is a viable option for out-of-office blood pressure monitoring and represents an evolution in the way blood pressure will be monitored in the future. Biobeat is a med-tech company with unique health-AI abilities and its wearable devices are FDA-Cleared for cuffless non-invasive blood pressure monitoring.
Customers
growth-positive
https://www.jpost.com/opinion/petach-tikvah-firm-develops-wireless-medical-monitoring-system-622545
BioBeat, a Petach Tikvah company, has developed a wireless medical monitoring system for monitoring coronavirus patients without hospitalization. The system, called BioBeat, consists of a sticker affixed to the chest that continuously monitors 16 advanced physiological metrics. The medical information is transmitted in real-time to the medical staff in the hospital, reducing contact between patients and medical teams. The system has been installed in 15 Israeli medical centers, including Ichilov, Tel Hashomer, Rambam, and Shaare Zedek. BioBeat is the only company in the world to hold FDA approval for continuous blood pressure measurement without the need for a pressure cuff. The company has raised $2.5 million in funding and has revenues of more than $10 million. BioBeat is owned by three founders: CEO Arik Ben Ishay, VP of technology Johanan May, and VP of research and development Israel Sarussi.
CustomersPartners
growth-positive
The Groundbreaking Biobeat Monitoring Platform Provides an Ideal Solution in Caring for Coronavirus Patients
Israeli company Biobeat has installed their monitoring platform in 11 hospitals across the country for Coronavirus patients. They are also working with authorities to implement monitoring of home hospitalized patients. Biobeats platform allows continuous monitoring of vital signs using a wireless, medical-grade, non-invasive optical sensor. The data is transmitted in real-time to the cloud and can be accessed remotely by medical staff. This reduces direct contact between patients and healthcare providers, minimizing the risk of exposure. Biobeat aims to analyze the influence of the virus on humans and the effectiveness of medical treatments using the data gathered from monitored subjects.
CustomersPartners
growth-positive
https://www.jpost.com/Israel-News/Coronavirus-facility-opens-at-Rambam-Hospital-using-new-Israeli-tech-619681
Rambam Hospital in Haifa has opened a new coronavirus department, which is isolated from the rest of the hospital. The department has separate facilities for patients and medical professionals, including an ambulance entrance and elevator. It can hold 30 patients and has specialized rooms for children and intubated patients. The department is staffed by 30 volunteer nurses and doctors from different departments. Patients have access to phones and video equipment to communicate with family and medical professionals. The department also utilizes a remote monitoring system developed by Israeli startup Biobeat. The system includes smart monitoring stickers that continuously monitor essential metrics of patients without physical contact. The Chinese Center for Disease Control and Prevention reported a decrease in new COVID-19 cases, while three new cases were announced in Israel.
Expand
growth-positive
The Biobeat Wearable Wristwatch and Patch Receive CE Mark Approval for Non-invasive Cuffless Monitoring of Blood Pressure, as Well as Cardiac Output, Stroke Volume, Pulse and Saturation
Biobeat, a bio-medical technology company, has received CE Mark approval for its patch and wristwatch for measuring various health parameters. The approval allows for remote medical grade monitoring of patients in the EU market. Biobeats products enable cloud-based healthcare and connectivity through smartphones or dedicated gateways. The company is focused on developing wireless medical-grade products that allow health providers to care for patients outside of their facility as efficiently as on-site. Biobeat has initiated sales in Israel and Europe and employs 15 employees.
CustomersPartners
growth-positive
BioBeat's Cuffless Blood Pressure Monitoring Device, USA
Biobeat Technologies BB-613WP, a cuffless blood pressure monitoring device, received FDA clearance for continuous measurement of blood pressure, blood oxygen saturation, and heart rate. The device is available as a wearable watch and disposable patch. It uses a patented reflective PPG sensor and transmits patient data in real-time. Biobeat received funding from BARDA for the development of the technology. The device has been clinically validated and is being sold in over 20 countries. Biobeat is now part of the TGH at Home program by Tampa General Hospital, providing remote patient monitoring.
CustomersPartnersInvestment
growth-positive
FDA approves Israeli co Biobeat's patch and watch
Israeli medical device company Biobeat has received FDA clearance for its patch and watch for measuring blood pressure, oxygenation, and heart rate. The clearance opens up opportunities for remote monitoring of vital signs in the US market. Biobeats products have already been approved in Europe and Israel. The companys CEO and Chief Medical Officer expressed excitement about the potential for remote care and the importance of novel medical-grade sensors. The article was published on August 26, 2019.
CustomersPartners
growth-positive
https://www.jpost.com/Jpost-Tech/Business-and-Innovation/Hillels-Tech-Corner-582108
Biobeat, a company based in Petah Tikva, has developed a wearable device that can replace traditional hospital monitors. The device, worn on the wrist, offers continuous, non-invasive monitoring of various parameters such as blood pressure and stroke volume. Biobeat has developed two products, a watch for chronic care patients and a patch for short-term monitoring. The products are intended for the professional medical market and have received regulatory approvals. Biobeat recently completed airworthiness testing of its patch with British Airways. The company is a finalist in the Best Wearable Mobile Technology competition at the Mobile World Congress, competing against companies like Samsung and Huawei.
CustomersInvestment
growth-positive
Wearable Suite Tracks Vitals for Alerts and Trends
In 2017, a shift was noted in wearable health tech towards clinical grade devices. This shift was driven by interest from the medical and research communities. Biobeat, an Israel-based company, has announced a pair of wearable devices that continuously monitor a wide range of patient vital signs. The suite includes a wristwatch, a single-use patch, a smartphone app for patients, and hospital screens and workstations. The devices report 16 health-related factors and all data is saved in Biobeat’s HIPAA- and GDPR-compliant cloud. The system also allows alert limits configured for each metric.
CustomersExpand
growth-positive
BARDA division helps fund Biobeat wearable health monitor in strategy to move diagnostics into individual hands - Homeland Preparedness News
Biobeat Technologies has received nearly $600,000 in funding from BARDAs DRIVe to develop its wrist watch-style health monitors. The technology is capable of monitoring vital signs and identifying illness before wearers display symptoms. The investment is part of BARDAs strategy to move identification of illness and diagnostics out of healthcare settings and onto the person. Biobeats wrist watch has already been cleared by the FDA for monitoring various health factors. With the funding, Biobeat will further develop the technology to track bodily changes that signal potential exposure to respiratory pathogens. BARDA is partnering with Biobeat and two other companies to develop health sensor technologies. The project is part of ENACT, a collection of products developed to empower patients with early health warnings.
PartnersInvestment
growth-positive
Blood pressure wearable device winners announced
The Westmead Applied Research Centre held a challenge to design a concept for a wearable blood pressure measuring device. The challenge received applications from all over Australia and internationally. The winner of the challenge was BioBeat Technologies, an Israeli-based technology company. They received a cash prize of $10,000. The second prize went to Team Suaning, who received a cash prize of $5,000 and mentoring sessions. The winners will move on to Phase 2 of the challenge for validation. The Westmead Applied Research Centre aims to improve health and wellbeing through collaboration and clinical translational research.
Customers
Biobeat Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 43 |
| Team members | 6 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 16 classification IDs that could be used for matching.
Biobeat Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 515356418 |
| Crunchbase | biobeat |
| Phone | +97239333022 |
| Creator | Benjamin Futoriansky |
| Creator email | ben.futor@gmail.com |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2024-11-10T00:00:00.000Z |
| Created | 2016-06-06T00:00:00.000Z |
| Claimed | Yes |